Format

Send to

Choose Destination
Int J Mol Sci. 2015 Jan 22;16(2):2320-51. doi: 10.3390/ijms16022320.

Cyclic nucleotide signalling in kidney fibrosis.

Author information

1
Pharmacology and Toxicology, University Regensburg, Regensburg 93053, Germany. elisabeth.schinner@chemie.uni-regensburg.de.
2
Pharmacology and Toxicology, University Regensburg, Regensburg 93053, Germany. Veronika.wetzl@chemie.uni-regensburg.de.
3
Pharmacology and Toxicology, University Regensburg, Regensburg 93053, Germany. jens.schlossmann@chemie.uni-regensburg.de.

Abstract

Kidney fibrosis is an important factor for the progression of kidney diseases, e.g., diabetes mellitus induced kidney failure, glomerulosclerosis and nephritis resulting in chronic kidney disease or end-stage renal disease. Cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP) were implicated to suppress several of the above mentioned renal diseases. In this review article, identified effects and mechanisms of cGMP and cAMP regarding renal fibrosis are summarized. These mechanisms include several signalling pathways of nitric oxide/ANP/guanylyl cyclases/cGMP-dependent protein kinase and cAMP/Epac/adenylyl cyclases/cAMP-dependent protein kinase. Furthermore, diverse possible drugs activating these pathways are discussed. From these diverse mechanisms it is expected that new pharmacological treatments will evolve for the therapy or even prevention of kidney failure.

PMID:
25622251
PMCID:
PMC4346839
DOI:
10.3390/ijms16022320
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Multidisciplinary Digital Publishing Institute (MDPI) Icon for PubMed Central
Loading ...
Support Center